author-photo

C. Assaid

Merck & Co.

3

Papers

1

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

2020 World Allergy Organization Journal
Show All
- Source
- Cite
- Save
Citations (0)
BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH

2020 Chest
Show All
- Source
- Cite
- Save
Citations (0)